Hostname: page-component-84b7d79bbc-7nlkj Total loading time: 0 Render date: 2024-07-26T22:08:49.286Z Has data issue: false hasContentIssue false
  • English
  • Français

Understanding the Latest Advances in Pharmacologic Interventions for Alzheimer's Disease

Published online by Cambridge University Press:  07 November 2014

Christopher H. van Dyck
Get access Rights & Permissions [Opens in a new window]

Abstract

Alzheimer's disease (AD) is a complex medical condition involving abnormalities in multiple biological and environmental domains. Current knowledge suggests that simultaneous intervention in these domains may be the most effective way to help AD patients and their families. Treatments for AD are centered on the inhibition of enzymes responsible for the degradation of acetylcholine—a neurotransmitter that is reduced in AD patients. Four cholinesterase inhibitors have been approved by the United States Food and Drug Administration, three of which are routinely used for the symptomatic treatment of mild-to-moderate AD. Strategies will be reviewed with regard to cognitive, functional, and behavioral domains. Providing a different treatment option for patients with AD, memantine is a low-to-moderate affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that has been approved for the treatment of moderate-to-severe AD. The clinical efficacy and tolerability of memantine monotherapy and combination therapy in patients with AD will be presented. Finally, the role of non-pharmacologic intervention will be discussed.

Type
Academic Supplement
Information
CNS Spectrums , Volume 9 , Issue S5: Assessing Current Practice in Alzheimer's Disease , July 2004 , pp. 24 - 28
Copyright
Copyright © Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Knapp, MJ, Knopman, DS, Solomon, PR, Pendlebury, WW, Davis, CS, Gracon, SI and the Tacrine Study Group. A 30-week tandomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994;271:985–991.Google Scholar
2.Rogers, SL, Farlow, MR, Doody, RS, Mohs, R, Friedhoff, LT and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136–145.CrossRefGoogle ScholarPubMed
3.Corey-Bloom, J, Anand, R, Veach, J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Ger Psychopharmacol. 1998;55–65.Google Scholar
4.Rosler, M, Anand, R, Cicin-Sain, A, et al.Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318:633–638.Google Scholar
5.Tariot, PN, Solomon, PR, Morris, JC, Kershaw, P, Lilienfeld, S, Ding, C and the Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269–2276.CrossRefGoogle ScholarPubMed
6.Reisberg, B, Doody, R, Stöffler, A, Schmitt, F, Ferris, S, Möbius, HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333–1341.CrossRefGoogle ScholarPubMed
7.Tariot, PN, Farlow, MR, Grossberg, GT, Graham, SM, McDonald, S, Gergel, I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317–324.Google Scholar
8.Sano, M, Ernesto, C, Thomas, RG, et al for the Alzheimer's Disease Cooperative Study. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997;336:1216–1222.CrossRefGoogle ScholarPubMed
9.Feldman, H, Gauthier, S, Hecker, J, Vellas, B, Subbiah, P, Whalen, E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57:613–620.CrossRefGoogle ScholarPubMed
10.Wenk, GL, Quack, G, Moebius, HJ, Danysz, W. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. 2000;66:1079–1083.Google Scholar